Publications by authors named "S Shikata"
Acute erythroleukemia (AEL) is a rare subtype of acute myeloid leukemia with a poor prognosis. In this study, we established a novel murine AEL model with Trp53 depletion and ERG overexpression. ERG overexpression in Trp53-deficient mouse bone marrow cells, but not in wild-type bone marrow cells, leads to AEL development within two months after transplantation with 100% penetrance.
View Article and Find Full Text PDFImmunotherapy has attracted considerable attention as a therapeutic strategy for cancers including acute myeloid leukemia (AML). In this study, we found that the development of several aggressive subtypes of AML is slower in Rag2 mice despite the lack of B and T lymphocytes, even compared to the immunologically normal C57BL/6 mice. Furthermore, an orally active p53-activating drug shows stronger antileukemia effect on AML in Rag2 mice than C57BL/6 mice.
View Article and Find Full Text PDFIntroduction: In treating acute hypoxemic respiratory failure (AHRF) caused by coronavirus disease 2019 (COVID-19), clinicians choose respiratory therapies such as low-flow nasal cannula oxygenation, high-flow nasal cannula oxygenation, or mechanical ventilation after assessment of the patient's condition. Chest computed tomography (CT) imaging contributes significantly to diagnosing COVID-19 pneumonia. However, the costs and potential harm to patients from radiation exposure need to be considered.
View Article and Find Full Text PDFAdjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics.
View Article and Find Full Text PDFArticle Synopsis
- The MonrachE trial used histological grade (HG) to select patients with high-risk HR-positive, HER2-negative early breast cancer, but the effectiveness of replacing HG with nuclear grade (NG) for patient selection is uncertain.
- A study reviewed 647 patients and categorized them into four groups based on axillary lymph node status, tumor grade, size, and proliferative index (Ki-67), and compared their invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS).
- Results showed that group 1, with higher cancer indicators, had worse outcomes compared to groups 2 and 3, and group 4 also demonstrated higher risk, suggesting NG is a valuable tool for assessing recurrence risk in these patients.